NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended against marketing authorization for Eli Llilly's Alzheimer's drug Kisunla ...
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback